GSK is expected to report profit of £4.4 billion for the first half of this year. AstraZeneca is forecast to report a ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Grocers Sainsbury ’s (LON: SBRY) and Marks & Spencer, Tesco (LON: TSCO) are next, along with easyjet (LON: EZJ ), with the ...

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.

ACA health plan premiums could spike in 2026: report Insurers are requesting a median premium increase of 15% for 2026, as payers grapple with policy uncertainty on tariffs and increased financial ...

Molina cuts 2025 earnings outlook again on ACA, Medicaid pressures The California-based insurer outlined its plans to survive what CEO Joe Zubretsky deemed a “season of great uncertainty.” ...